We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$1.94B
1-Year Est. Return
444.09%
This Fund
S&P 500
This Quarter
Est. Return
+47.39%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$441M
(+29%)
Cap. Flow
+$158M
Cap. Flow
% of AUM
8.14%
Top 10 Holdings %
Top 10 Hldgs %
50.91%
Holding
78
New
12
Increased
23
Reduced
21
Closed
13
Top Buys
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$49.2M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$40.6M |
| 3 |
United Therapeutics
UTHR
|
+$39.8M |
| 4 |
Cytokinetics
CYTK
|
+$36.5M |
| 5 |
ABVX
Abivax
ABVX
|
+$32.5M |
Top Sells
| 1 |
CDTX
Cidara Therapeutics
CDTX
|
+$68.5M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$36.1M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$34M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$27.8M |
| 5 |
Erasca
ERAS
|
+$21.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$39.2B
| $195M | 10.02% |
2,000,000
| – | – |
|
|
2
Erasca
ERAS
$6.61B
| $180M | 9.29% |
11,150,000
-1,850,000
| -14% | -$21.9M |
|
3
IDEAYA Biosciences
IDYA
$3.54B
| $115M | 5.92% |
3,450,000
+325,000
| +10% | +$10.9M |
|
|
4
Praxis Precision Medicines
PRAX
$8.88B
| $91.8M | 4.73% |
285,000
-90,000
| -24% | -$27.8M |
|
|
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
| $84.4M | 4.35% |
2,125,000
+1,925,000
| +963% | +$49.2M |
|
|
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
| $79.1M | 4.07% |
1,500,000
+750,000
| +100% | +$30.8M |
|
|
ABVX
7
Abivax
ABVX
$11.9B
| $75.2M | 3.87% |
675,000
+275,000
| +69% | +$32.5M |
|
8
Tango Therapeutics
TNGX
$4.93B
| $62.8M | 3.23% |
3,000,000
-1,200,000
| -29% | -$16.7M |
|
|
9
Cytokinetics
CYTK
$11.2B
| $57.7M | 2.97% |
875,000
+575,000
| +192% | +$36.5M |
|
10
Olema Pharmaceuticals
OLMA
$1.03B
| $47.8M | 2.46% |
3,208,875
| – | – |
|
|
11
United Therapeutics
UTHR
$22.6B
| $47.4M | 2.44% |
+80,000
| New | +$39.8M |
|
12
Immunocore
IMCR
$1.76B
| $45.2M | 2.33% |
1,500,000
+650,000
| +76% | +$21M |
|
|
13
Madrigal Pharmaceuticals
MDGL
$12.7B
| $44.5M | 2.29% |
+85,000
| New | +$40.6M |
|
14
Rhythm Pharmaceuticals
RYTM
$7.52B
| $39.1M | 2.02% |
450,000
+260,000
| +137% | +$25.3M |
|
15
CG Oncology
CGON
$6.44B
| $38.9M | 2% |
575,000
+375,000
| +188% | +$21.2M |
|
|
MAZE
16
Maze Therapeutics
MAZE
$1.63B
| $36.9M | 1.9% |
1,235,000
+285,000
| +30% | +$12.6M |
|
17
Biogen
BIIB
$29.1B
| $36.7M | 1.89% |
200,000
| – | – |
|
18
Disc Medicine
IRON
$2.9B
| $35.8M | 1.84% |
560,000
+50,000
| +10% | +$3.47M |
|
19
Dianthus Therapeutics
DNTH
$5.46B
| $33.6M | 1.73% |
400,000
+85,000
| +27% | +$4.92M |
|
20
Ocular Therapeutix
OCUL
$2.18B
| $32.6M | 1.68% |
3,850,000
+350,000
| +10% | +$3.34M |
|
21
Tyra Biosciences
TYRA
$1.93B
| $32.6M | 1.68% |
850,000
+640,000
| +305% | +$20.7M |
|
22
Trevi Therapeutics
TRVI
$2.58B
| $28.6M | 1.47% |
2,400,000
+850,000
| +55% | +$9.52M |
|
23
MoonLake Immunotherapeutics
MLTX
$1.67B
| $28M | 1.44% |
1,500,000
-250,000
| -14% | -$4.14M |
|
24
Immunovant
IMVT
$8.19B
| $26.7M | 1.38% |
1,075,000
-300,000
| -22% | -$7.77M |
|
|
TERN
25
CALL
DELISTED
Terns Pharmaceuticals
TERN
| $26.4M | 1.36% |
+500,000
| New | +$20.5M |
|
Similar funds
NFG
FFH
BC
MWA
WPC
OCM
1SB
FM